BSE Live
Apr 02, 16:01Prev. Close
5.23
Open Price
5.79
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of DECIPHER LABS (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | -0.44 | 0.02 | -2.59 | 0.36 | 0.10 | |
| Diluted EPS (Rs.) | -0.44 | 0.02 | -2.59 | 0.36 | 0.10 | |
| Cash EPS (Rs.) | -0.42 | 0.04 | -2.53 | 0.41 | 0.14 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 8.40 | 8.84 | 8.82 | 11.41 | 11.05 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 8.40 | 8.84 | 8.82 | 11.41 | 11.05 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 0.84 | 3.50 | 0.80 | 0.98 | 0.97 | |
| PBDIT/Share (Rs.) | -0.42 | 0.04 | -0.34 | 0.40 | 0.16 | |
| PBIT/Share (Rs.) | -0.43 | 0.02 | -0.39 | 0.35 | 0.12 | |
| PBT/Share (Rs.) | -0.43 | 0.02 | -2.61 | 0.35 | 0.10 | |
| Net Profit/Share (Rs.) | -0.44 | 0.02 | -2.59 | 0.36 | 0.10 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | -49.49 | 1.12 | -41.97 | 41.27 | 16.37 | |
| PBIT Margin (%) | -51.45 | 0.71 | -49.06 | 36.21 | 12.12 | |
| PBT Margin (%) | -51.45 | 0.71 | -325.79 | 36.21 | 10.28 | |
| Net Profit Margin (%) | -51.59 | 0.65 | -323.14 | 36.46 | 9.85 | |
| Return on Networth / Equity (%) | -5.18 | 0.26 | -29.39 | 3.12 | 0.86 | |
| Return on Capital Employed (%) | -5.17 | 0.28 | -4.46 | 3.10 | 1.05 | |
| Return on Assets (%) | -4.79 | 0.18 | -29.11 | 3.10 | 0.84 | |
| Total Debt/Equity (X) | 0.03 | 0.00 | 0.00 | 0.00 | 0.01 | |
| Asset Turnover Ratio (%) | 0.08 | 0.32 | 0.08 | 0.09 | 8.56 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 0.47 | 1.04 | 2.15 | 32.36 | 11.77 | |
| Quick Ratio (X) | 0.47 | 1.04 | 2.15 | 31.81 | 11.58 | |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | 22.08 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 10.80 | 14.89 | 14.28 | 53.43 | 33.90 | |
| EV/Net Operating Revenue (X) | 12.66 | 4.22 | 17.62 | 54.06 | 34.74 | |
| EV/EBITDA (X) | -25.59 | 376.04 | -41.99 | 130.96 | 212.15 | |
| MarketCap/Net Operating Revenue (X) | 12.44 | 4.22 | 17.69 | 54.11 | 34.62 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 1.25 | 1.67 | 1.61 | 4.64 | 3.03 | |
| Price/Net Operating Revenue | 12.45 | 4.22 | 17.72 | 54.14 | 34.63 | |
| Earnings Yield | -0.04 | 0.00 | -0.18 | 0.01 | 0.00 |
26.11.2025
DECIPHER LABS Consolidated September 2025 Net Sales at Rs 4.31 crore, down 26.47% Y-o-Y
24.11.2025
DECIPHER LABS Standalone September 2025 Net Sales at Rs 0.09 crore, up 5.01% Y-o-Y
10.06.2025
DECIPHER LABS Standalone March 2025 Net Sales at Rs 0.23 crore, down 93.27% Y-o-Y
03.06.2025
DECIPHER LABS Consolidated March 2025 Net Sales at Rs 3.50 crore, down 66.95% Y-o-Y
26.11.2025
DECIPHER LABS Consolidated September 2025 Net Sales at Rs 4.31 crore, down 26.47% Y-o-Y
24.11.2025
DECIPHER LABS Standalone September 2025 Net Sales at Rs 0.09 crore, up 5.01% Y-o-Y
10.06.2025
DECIPHER LABS Standalone March 2025 Net Sales at Rs 0.23 crore, down 93.27% Y-o-Y
03.06.2025
DECIPHER LABS Consolidated March 2025 Net Sales at Rs 3.50 crore, down 66.95% Y-o-Y
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth